176 related articles for article (PubMed ID: 28202657)
1. Deciphering the RAS/ERK pathway
Dorard C; Vucak G; Baccarini M
Biochem Soc Trans; 2017 Feb; 45(1):27-36. PubMed ID: 28202657
[TBL] [Abstract][Full Text] [Related]
2. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
3. Protein-Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway.
García-Gómez R; Bustelo XR; Crespo P
Trends Cancer; 2018 Sep; 4(9):616-633. PubMed ID: 30149880
[TBL] [Abstract][Full Text] [Related]
4. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
5. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
6. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of the ERK mitogen-activated protein kinase cascade for targeting RAS mutant cancers.
Gentry L; Samatar AA; Der CJ
Enzymes; 2013; 34 Pt. B():67-106. PubMed ID: 25034101
[TBL] [Abstract][Full Text] [Related]
8. Post-transcriptional regulation of the Ras-ERK/MAPK signaling pathway.
Whelan JT; Hollis SE; Cha DS; Asch AS; Lee MH
J Cell Physiol; 2012 Mar; 227(3):1235-41. PubMed ID: 21688267
[TBL] [Abstract][Full Text] [Related]
9. New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling.
Erickson KE; Rukhlenko OS; Posner RG; Hlavacek WS; Kholodenko BN
Semin Cancer Biol; 2019 Feb; 54():162-173. PubMed ID: 29518522
[TBL] [Abstract][Full Text] [Related]
10. Ras-Erk signaling induces phosphorylation of human TLE1 and downregulates its repressor function.
Zahavi T; Maimon A; Kushnir T; Lange R; Berger E; Kornspan D; Grossman R; Anzi S; Shaulian E; Karni R; Nechushtan H; Paroush Z
Oncogene; 2017 Jun; 36(26):3729-3739. PubMed ID: 28192406
[TBL] [Abstract][Full Text] [Related]
11. [Roles of targeting Ras/Raf/MEK/ERK signaling pathways in the treatment of esophageal carcinoma].
Chang YS; Liu JC; Fu HQ; Yu BT; Zou SB; Wu QC; Wan L
Yao Xue Xue Bao; 2013 May; 48(5):635-41. PubMed ID: 23888683
[TBL] [Abstract][Full Text] [Related]
12. Clinical Translation of Combined MAPK and Autophagy Inhibition in
Lee JJ; Jain V; Amaravadi RK
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830283
[No Abstract] [Full Text] [Related]
13. MEK in cancer and cancer therapy.
Neuzillet C; Tijeras-Raballand A; de Mestier L; Cros J; Faivre S; Raymond E
Pharmacol Ther; 2014 Feb; 141(2):160-71. PubMed ID: 24121058
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer.
Sharma SB; Ruppert JM
Drug Dev Res; 2015 Sep; 76(6):328-42. PubMed ID: 26284568
[TBL] [Abstract][Full Text] [Related]
15. p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model.
Chow HY; Jubb AM; Koch JN; Jaffer ZM; Stepanova D; Campbell DA; Duron SG; O'Farrell M; Cai KQ; Klein-Szanto AJ; Gutkind JS; Hoeflich KP; Chernoff J
Cancer Res; 2012 Nov; 72(22):5966-75. PubMed ID: 22983922
[TBL] [Abstract][Full Text] [Related]
16. CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the Kit-, Ras/Raf/Erk- and Akt-pathways.
Schulte SL; Waha A; Steiger B; Denkhaus D; Dörner E; Calaminus G; Leuschner I; Pietsch T
Oncotarget; 2016 Aug; 7(34):55026-55042. PubMed ID: 27391150
[TBL] [Abstract][Full Text] [Related]
17. The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells.
Noser JA; Mael AA; Sakuma R; Ohmine S; Marcato P; Lee PW; Ikeda Y
Mol Ther; 2007 Aug; 15(8):1531-6. PubMed ID: 17505473
[TBL] [Abstract][Full Text] [Related]
18. Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma.
Benoit A; Bou-Petit E; Chou H; Lu M; Guilbert C; Luo VM; Assouline S; Morin RD; Dmitrienko S; Estrada-Tejedor R; Johnson NA; Mann KK
Sci Rep; 2022 Jan; 12(1):779. PubMed ID: 35039569
[TBL] [Abstract][Full Text] [Related]
19. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.
McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Montalto G; Cervello M; Nicoletti F; Fagone P; Malaponte G; Mazzarino MC; Candido S; Libra M; Bäsecke J; Mijatovic S; Maksimovic-Ivanic D; Milella M; Tafuri A; Cocco L; Evangelisti C; Chiarini F; Martelli AM
Oncotarget; 2012 Sep; 3(9):954-87. PubMed ID: 23006971
[TBL] [Abstract][Full Text] [Related]
20. Canonical RTK-Ras-ERK signaling and related alternative pathways.
Sundaram MV
WormBook; 2013 Jul; ():1-38. PubMed ID: 23908058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
